Bio-Techne Stock Forecast, Price & News

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bio-Techne in the last twelve months. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Bio-Techne stock.
View analyst ratings for Bio-Techne or view top-rated stocks.

Wall Street analysts have given Bio-Techne a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Bio-Techne wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Bio-Techne saw a increase in short interest in March. As of March 15th, there was short interest totaling 406,400 shares, an increase of 45.9% from the February 28th total of 278,600 shares. Based on an average daily volume of 196,200 shares, the short-interest ratio is presently 2.1 days.
View Bio-Techne's Short Interest.

Bio-Techne is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Bio-Techne.

Bio-Techne will be holding an earnings conference call on Thursday, May 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Bio-Techne Co. (NASDAQ:TECH) announced its earnings results on Monday, February, 1st. The biotechnology company reported $1.62 earnings per share for the quarter, topping the consensus estimate of $1.37 by $0.25. The biotechnology company had revenue of $224.30 million for the quarter, compared to the consensus estimate of $206.50 million. Bio-Techne had a net margin of 32.69% and a trailing twelve-month return on equity of 12.20%. The business's revenue for the quarter was up 21.3% compared to the same quarter last year. During the same quarter last year, the business earned $1.08 EPS.
View Bio-Techne's earnings history.

Bio-Techne's stock was trading at $180.58 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, TECH stock has increased by 126.3% and is now trading at $408.72.
View which stocks have been most impacted by COVID-19.

Bio-Techne declared a quarterly dividend on Wednesday, February 3rd. Stockholders of record on Friday, February 12th will be paid a dividend of $0.32 per share on Friday, February 26th. This represents a $1.28 annualized dividend and a dividend yield of 0.31%. The ex-dividend date of this dividend is Thursday, February 11th.
View Bio-Techne's dividend history.

Bio-Techne pays an annual dividend of $1.28 per share and currently has a dividend yield of 0.32%. Bio-Techne does not yet have a strock track record of dividend growth. The dividend payout ratio of Bio-Techne is 33.16%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Bio-Techne will have a dividend payout ratio of 21.88% next year. This indicates that Bio-Techne will be able to sustain or increase its dividend.
View Bio-Techne's dividend history.

10 equities research analysts have issued 1-year price objectives for Bio-Techne's shares. Their forecasts range from $220.00 to $440.00. On average, they anticipate Bio-Techne's stock price to reach $367.50 in the next twelve months. This suggests that the stock has a possible downside of 10.1%.
View analysts' price targets for Bio-Techne or view top-rated stocks among Wall Street analysts.

95 employees have rated Bio-Techne CEO Charles Kummeth on Glassdoor.com. Charles Kummeth has an approval rating of 73% among Bio-Techne's employees.

Some companies that are related to Bio-Techne include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO), Charles River Laboratories International (CRL), PerkinElmer (PKI), Bruker (BRKR), Pacific Biosciences of California (PACB), Luminex (LMNX), Fluidigm (FLDM), Harvard Bioscience (HBIO), aTyr Pharma (LIFE) and BG Medicine (BGMD).
View all of TECH's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Techne investors own include Paychex (PAYX), Gilead Sciences (gild), NVIDIA (NVDA), AbbVie (ABBV), Amgen (AMGN), Abbott Laboratories (ABT), Cisco Systems (CSCO), Johnson & Johnson (JNJ), AT&T (T) and The Boeing (BA).

Bio-Techne trades on the NASDAQ under the ticker symbol "TECH."

Bio-Techne's stock is owned by a number of institutional and retail investors. Top institutional shareholders include State of Alaska Department of Revenue (0.06%), Fulcrum Equity Management (0.01%) and Pacer Advisors Inc. (0.01%). Company insiders that own Bio-Techne stock include Alpna Seth, Brenda S Furlow, Charles R Kummeth, Harold J Wiens, James Hippel, John L Higgins, Kim Kelderman, Norman David Eansor, Robert V Baumgartner and Roeland Nusse.
View institutional ownership trends for Bio-Techne.

TECH stock was acquired by a variety of institutional investors in the last quarter, including Fulcrum Equity Management, Pacer Advisors Inc., and State of Alaska Department of Revenue. Company insiders that have bought Bio-Techne stock in the last two years include Charles R Kummeth, and Robert V Baumgartner.
View insider buying and selling activity for Bio-Techne or or view top insider-buying stocks.

Shares of TECH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TECH stock can currently be purchased for approximately $408.72.

Bio-Techne has a market capitalization of $15.86 billion and generates $738.69 million in revenue each year. The biotechnology company earns $229.30 million in net income (profit) each year or $3.86 on an earnings per share basis.

Bio-Techne employs 2,300 workers across the globe.

The following companies are subsidiares of Bio-Techne: Advanced Cell Diagnostics, Advanced Cell Diagnostics Inc., B-MoGen Biotechnologies Inc., Bio-Techne China Co. Ltd, Bio-Techne Ltd., Bionostics Inc., CLINIQA Corporation, CyVek, Exosome Diagnostics, Exosome Diagnostics Inc., MoGen Biotechnologies, Novus Biologicals, Novus Biologicals LLC, ProteinSimple, ProteinSimple Ltd., QT Holdings Corporation, Quad Technologies, Research and Diagnostic Systems Inc., Shanghai PrimeGene Bio-Tech Co. Ltd., Space Import-Export Srl, Tocris Cookson Limited, and Zephyrus Biosciences.

Bio-Techne was founded in 1981.

The official website for Bio-Techne is www.bio-techne.com.

Bio-Techne is headquartered at 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413.

Bio-Techne's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The biotechnology company can be reached via phone at 612-379-8854 or via email at [email protected]